Calidi Biotherapeutics Terminates Material Agreement
Ticker: CLDWW · Form: 8-K · Filed: Jan 28, 2025 · CIK: 1855485
| Field | Detail |
|---|---|
| Company | Calidi Biotherapeutics, Inc. (CLDWW) |
| Form Type | 8-K |
| Filed Date | Jan 28, 2025 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $0.0001, $25.0 million, $9.5 million, $2.0 million, $3.1 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: agreement-termination, financial-update, operations-update
TL;DR
Calidi Biotherapeutics terminated a key deal, filing an 8-K with operational and financial updates.
AI Summary
Calidi Biotherapeutics, Inc. announced on January 23, 2025, the termination of a material definitive agreement. The company also provided updates on its results of operations and financial condition, along with a Regulation FD disclosure. This filing includes financial statements and exhibits related to these events.
Why It Matters
The termination of a material definitive agreement could significantly impact Calidi Biotherapeutics' ongoing operations, strategic partnerships, or financial standing.
Risk Assessment
Risk Level: medium — Termination of a material definitive agreement introduces uncertainty regarding the company's future business relationships and financial projections.
Key Players & Entities
- Calidi Biotherapeutics, Inc. (company) — Registrant
- January 23, 2025 (date) — Earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-40789 (identifier) — Commission File Number
- 86-2967193 (identifier) — I.R.S. Employer Identification No.
- 4475 Executive Drive, Suite 200, San Diego, California 92121 (address) — Principal business address
- First Light Acquisition Group, Inc. (company) — Former company name
- 20210406 (date) — Date of former company name change
FAQ
What was the specific material definitive agreement that was terminated?
The filing states the termination of a material definitive agreement but does not specify which agreement was terminated.
What are the key details regarding the results of operations and financial condition?
The filing indicates that results of operations and financial condition are being reported, but specific details are not provided in the provided text.
What is the nature of the Regulation FD Disclosure?
The filing mentions a Regulation FD Disclosure, but the specific content of this disclosure is not detailed in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on January 23, 2025.
What is Calidi Biotherapeutics, Inc.'s primary business classification?
Calidi Biotherapeutics, Inc. is classified under BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) with SIC code 2836.
Filing Stats: 1,726 words · 7 min read · ~6 pages · Grade level 13.3 · Accepted 2025-01-28 08:30:32
Key Financial Figures
- $0.0001 — ch Registered Common stock, par value $0.0001 per share CLDI NYSE American LLC
- $25.0 million — n, to issue and sell to Yorkville up to $25.0 million of its shares of common stock, which ri
- $9.5 million — through two public offerings, it raised $9.5 million in gross proceeds, before deducting exp
- $2.0 million — ore deducting expenses, supplemented by $2.0 million from warrant exercises and $3.1 million
- $3.1 million — $2.0 million from warrant exercises and $3.1 million from its at-the-market ("ATM") program.
- $4.25 million — lic offering, that raised an additional $4.25 million in gross proceeds, before deducting exp
Filing Documents
- form8-k.htm (8-K) — 55KB
- ex99-1.htm (EX-99.1) — 18KB
- 0001493152-25-003916.txt ( ) — 254KB
- cldi-20250123.xsd (EX-101.SCH) — 3KB
- cldi-20250123_lab.xml (EX-101.LAB) — 33KB
- cldi-20250123_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. CALIDI BIOTHERAPEUTICS, INC. Dated: January 28, 2025 By: /s/ Andrew Jackson Name: Andrew Jackson Title: Chief Financial Officer